Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
May 09, 2024 07:00 ET | Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics today reported business highlights and financial results for the first quarter ending March 31, 2024.
selectION Announces Positive Results from Phase 1b Clinical Trial Evaluating si-544 in Patients with Atopic Dermatitis
April 29, 2024 04:00 ET | AKAMPION
si-544 was well tolerated with no serious adverse effects, dose limiting toxicities, or safety signals observed75% of patients receiving si-544 experienced objective clinical improvement, of which 44%...
PolTREG identifies promising efficacy biomarker for Type-1 diabetes in patients treated with its Treg therapy in combination with rituximab
April 04, 2024 01:00 ET | PolTREG S.A.
New biomarker may facilitate monitoring T1D patients’ healthIncrease in PD-1+ T-cells correlated with therapeutic response and less insulin use Gdańsk, Poland – 4 April 2024 – PolTREG S.A. (Warsaw...
Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases
March 28, 2024 09:00 ET | Mustang Bio, Inc.
Planning for proof-of concept Phase 1 investigator-sponsored clinical trial evaluating MB-106 CD20-targeted CAR T-cell therapy in autoimmune diseases is underway and expected to initiate in the fourth...
Emergen logo.png
Protein Therapeutics Market Size Worth USD 315.25 Billion in 2032 | Emergen Research
January 31, 2024 08:02 ET | Emergen Research
Vancouver, Jan. 31, 2024 (GLOBE NEWSWIRE) -- The global protein therapeutics market size was USD 152.28 Billion in 2022 and is expected to register a rapid revenue CAGR of 7.6% during the forecast...
selectION, Inc. to Present Update on Clinical Progress at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on January 11, 2024
January 05, 2024 04:00 ET | AKAMPION
Best-in-class Kv1.3 blocker has successfully completed a Phase 1b trial in atopic dermatitis patientsPipeline molecule to treat T cell mediated autoimmune diseases San Diego, CA, USA, and...
Autoimmune Diseases Diagnostics Global Market to Surpass 6 Billion Mark by 2028 | DelveInsight
December 21, 2023 13:00 ET | DelveInsight Business Research LLP
New York, USA, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Autoimmune Diseases Diagnostics Global Market to Surpass 6 Billion Mark by 2028 | DelveInsight The increasing prevalence of autoimmune disorders,...
Research Nester Logo.jpg
Epigenetics Market revenue to hit USD 5 Billion by 2035, says Research Nester
November 07, 2023 07:00 ET | Research Nester
New York , Nov. 07, 2023 (GLOBE NEWSWIRE) -- The global epigenetics market size is poised to grow at a CAGR of over 17% from 2023 to 2035. The market is anticipated to garner a revenue of USD 5...
GRI Bio Presents Data Supporting Innovative Pipeline of NKT Cell Modulators for the Treatment of High-Value Inflammatory, Fibrotic and Autoimmune Diseases
October 31, 2023 08:45 ET | GRI Bio, Inc.
Data presented at the 7th Annual Antifibrotic Drug Development (AFDD) Summit Company’s lead program, GRI-0621, has demonstrated ability to inhibit the activity of type I invariant NKT (iNKT) cells...
GRI Bio Announces Publication of Comprehensive Invariant NKT (iNKT) Cell Review in Frontiers in Immunology Demonstrating a Key Role of Type 1 iNKT Cells in Modulating Various Fibrotic Conditions
October 05, 2023 08:45 ET | GRI Bio, Inc.
In several murine models of chronic inflammation and fibrosis, as well as in humans, it has been shown that iNKT cells are selectively activated in the disease setting Data supports GRI Bio’s...